[1]卢海霞,覃柞莲,陆丽娟,等.黄芪甲苷抗肾纤维化的相关分子机制研究[J].西部中医药,2022,35(03):145-151.[doi:10.12174/j.issn.2096-9600.2022.03.34]
 LU Haixia,QIN Zuolian,LU Lijuan,et al.Advances in Molecular Mechanism of Astragaloside IV on Renal Fibrosis[J].Western Journal of Traditional Chinese Medicine,2022,35(03):145-151.[doi:10.12174/j.issn.2096-9600.2022.03.34]
点击复制

黄芪甲苷抗肾纤维化的相关分子机制研究
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年03期
页码:
145-151
栏目:
研究进展
出版日期:
2022-03-15

文章信息/Info

Title:
Advances in Molecular Mechanism of Astragaloside IV on Renal Fibrosis
作者:
卢海霞 覃柞莲 陆丽娟 吴炳瑶 谢丽 李丽
广西中医药大学第一附属医院,广西 南宁 530001
Author(s):
LU Haixia QIN Zuolian LU Lijuan WU Bingyao XIE Li LI Li
The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530001, China
关键词:
肾纤维化分子机制黄芪甲苷综述
Keywords:
renal fibrosismolecular mechanismastragaloside IVreview
分类号:
R256
DOI:
10.12174/j.issn.2096-9600.2022.03.34
文献标志码:
A
摘要:
通过综述肾纤维化的发生机制、黄芪甲苷(astragaloside IV,AS-IV)抗肾间质纤维化的分子机制及含AS-IV的抗肾纤维进程的相关中成药及注射剂探讨AS-IV抗肾纤维化的相关分子机制研究进展,指出已有研究证实AS-IV主要通过剂量依赖等方式阻止及防范足细胞凋亡及抑制肾脏纤维化。
Abstract:
Research progress on molecular mechanism of AS-IV against renal fibrosis was discussed by reviewing the pathogenesis of renal fibrosis, molecular mechanism of AS-IV on renal interstitial fibrosis, the related Chinese patent medicine and injections containing AS-IV against the progression of renal fibrosis. The previous studies have confirmed that AS mainly prevent podocyte apoptosis and inhibit renal fibrosis in a dose-dependent manner.

相似文献/References:

[1]邹荣,肖方喜,熊飞,等.肾衰合剂通过PKA信号通路抑制肾纤维化的实验观察[J].西部中医药,2015,28(06):4.[doi:2015/6/16 0:00:00]
[2]晁旭,李宏,王国全,等.贝母素乙诱导人肝癌SMMC-7721细胞凋亡的分子机制研究[J].西部中医药,2020,33(03):26.[doi:10.12174/j.issn.1004-6852.2020.03.07]
 CHAO Xu,LI Hong,et al.Research on Molecular Mechanism of the Apoptosis of Human Liver Cancer SMMC-7721 Cells Induced by Peiminine[J].Western Journal of Traditional Chinese Medicine,2020,33(03):26.[doi:10.12174/j.issn.1004-6852.2020.03.07]
[3]石威,张俊忠,解鹏超,等.基于网络药理学和分子对接探析淫羊藿-牛膝药对治疗股骨头坏死的作用机制[J].西部中医药,2022,35(04):35.[doi:10.12174/j.issn.2096-9600.2022.04.09]
 SHI Wei,ZHANG Junzhong,XIE Pengchao,et al.Study on the Mechanism of Yinyanghuo-Niuxi Drug Pair in Treating Femoral Head Necrosis Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2022,35(03):35.[doi:10.12174/j.issn.2096-9600.2022.04.09]
[4]盖银玲,王媛媛,杨小春,等.芪实益肾方联合缬沙坦治疗慢性肾小球肾炎的疗效及对炎症因子、肾纤维化指标的影响[J].西部中医药,2022,35(05):119.[doi:10.12174/j.issn.2096-9600.2022.05.27]
 GAI Yinling,WANG Yuanyuan,YANG Xiaochun,et al.Clinical Effects of Qishi Benefiting-kidney Prescription in Combination with Valsartan in the Treatment of Chronic Glomerulonephritis and Its Influence on Inflammatory Factors and Renal Fibrosis Indexes[J].Western Journal of Traditional Chinese Medicine,2022,35(03):119.[doi:10.12174/j.issn.2096-9600.2022.05.27]
[5]郑丹如,卢海霞,许禄华,等.八珍汤促宫颈成熟分子机制和生物通路的网络药理学研究[J].西部中医药,2021,34(11):56.[doi:10.12174/j.issn.2096-9600.2021.11.12]
 ZHENG Danru,LU Haixia,XU Luhua,et al.Network Pharmacological Study on Molecular Mechanism and Biological Pathway of Bazhen Decoction in Promoting Cervical Maturation[J].Western Journal of Traditional Chinese Medicine,2021,34(03):56.[doi:10.12174/j.issn.2096-9600.2021.11.12]

备注/Memo

备注/Memo:
卢海霞(1984—),女,主管护师。研究方向:肾病肾纤维的护理研究。
更新日期/Last Update: 2022-06-24